encounter brain metastases. Little is known, however, regarding management of elderly patients with brain metastases. Therefore, clinicians are often uncertain as to the optimal treatment for these patients-that is, whole-brain radiotherapy (WBRT), surgery, stereotactic radiosurgery (SRS), radiotherapy, administration of anticancer agents, or combinations of these modalities, efficacies of which vary among patient subsets.
SRS has recently been reported to be effective for the treatment of brain metastases in older patients, with various studies reporting on its successful use in patients 65 years or older, 19 70 years or older, 17 and 75 years or older. 13 Furthermore, an increasing number of patients with brain metastases, even patients older than 80 years, have been treated with SRS. Little information is, however, available on SRS for these older patients. Thus, using our own database, we reappraised whether the results of SRS treatment in patients 80 years or older differ from the results in patients 65-79 years old.
As aging of the population is proceeding very quickly in Japan, considerable numbers of symposia and panel discussions, not only at neurosurgery congresses but also at those for other medical specialties, are increasingly focusing on treatment of patients 80 years of age and older. Therefore, we used age 80 years as the cut-off point in this study. This means that the categorization applied herein was based on neither medical nor radiobiological evidence. Univariate analysis with age as a continuous variable for overall survival using our most recently revised database including 2552 brain metastasis patients treated with SRS alone yielded a hazard ratio (HR) of 1.009, 95% confidence interval (CI) of 1.006-1.013, and p < 0.0001 (unpublished data). This HR is very close to "1" and can thus be clinically interpreted as indicating that patient age has little, if any, impact on overall survival even though, due to the large patient number, the p value was very low.
Methods

Patient Population
This retrospective cohort study used our prospectively accumulated database at Katsuta Hospital Mito Gammahouse, which included, at the time of the study, 2552 consecutive cases. The study was approved by the institutional review board of Tokyo Women's Medical University. Patients in our series underwent SRS alone, not in combination with concurrent WBRT, for treatment of brain metastases during the 13-year period between July 1998 and June 2011. As all patients had been referred to us for SRS, in most cases the patient selections were made by the patients' primary physicians. Patient selection criteria may thus have differed among referring physicians. Therefore, in each case, one author (M.Y.) decided whether the patient could be treated with SRS. We did not treat patients with SRS if they had low Karnofsky Performance Status (KPS) 12 scores due to systemic disease (< 70%), an uncooperative state due to poor neurocognitive function, meningeal dissemination, or an anticipated survival period of 3 months or less. Among the 2552 patients, we studied 1346 who were at least 65 years of age at the time of SRS. These 1346 patients were divided into 2 groups: 165 patients 80 years of age or older (Group A) and 1181 patients 65-79 years of age (Group B). Table 1 summarizes clinical characteristics overall and for the 2 age groups. Because all patients had been referred to us for SRS by other facilities, the primary physicians responsible for each patient had decided the indications for both surgery and radiotherapy, and 217 (16.1%) of the 1346 patients had undergone surgical removal of brain metastases prior to SRS and 49 (3.6%) had undergone WBRT.
Before SRS, the treatment strategy was explained in detail to each patient and at least one adult relative by the second author (M.Y.). Written informed consent was obtained from all patients. We have described our radiosurgical techniques in detail in previous reports. 30, 32 Briefly, standard SRS procedures were performed using a Leksell Gamma Knife Model B (Elekta AB) before June 2003 and thereafter a Leksell Gamma Knife Model C (Elekta AB). Regarding dose selection in cases involving elderly patients, we did not take patient age into consideration.
After SRS, all cases were routinely managed by referring physicians, with a recommendation for follow-up clinical and neuroimaging examinations at an approximately 2-to 3-month interval. However, in 449 (33.4%) of the 1346 patients, neuroimaging follow-up could not be performed due to early post-SRS death or marked deterioration of general condition. Approximately 50% of our 1346 patients came to our outpatient clinic periodically, while clinical and/or neuroimaging data were sent to us by post in about 25% of cases. The second author (M.Y.) called the remaining 25% of patients or their relatives by telephone to confirm the patients' conditions. For deceased patients, the day of death, cause of death, and detailed information on patient condition changes were requested by telephone.
Case Matching
As shown in Table 1 , there was bias and a large difference in numbers of patients between Groups A and B. Therefore, a case-matched study was conducted by one of the authors (Y.S.), who did not participate in other aspects of this study and was blinded to final outcomes. Patient selection was performed by employing the propensity score matching method with a Greedy 5-To-1 Digit-Matching algorithm 20 for 2 clinical factors, KPS score and prior surgery.
Clinical Outcomes
The primary end point was overall survival, and the secondary end points were neurological death, neurological deterioration, local recurrence of the treated tumor, repeat SRS for new lesions, and SRS-induced major complications. For each end point, failures were regarded as events and any others as censored. Overall survival time was defined as the interval between the first SRS and death due to any cause (progression of systemic metastases and/ or brain metastases, other disease unrelated to cancer, accident, suicide, and so on) or the day of the last follow-up. Neurological death was defined as death caused by any intracranial disease, including tumor recurrence, carcinomatous meningitis, cerebral dissemination, and progression of other untreated intracranial tumors.
Local recurrence-free survival time was defined as the interval between the first SRS and the day when follow-up MRI demonstrated local recurrence (at the irradiated lesion). Generally, local recurrence criteria were increased size of an enhanced area on post-gadolinium T1-weighted MR images and enlarged tumor core on T2-weighted MR images. 10 However, in 41 cases in which MRI alone was not sufficient to confirm recurrence, 11 C methionine positron emission tomography (PET) was used to distinguish tumor recurrence from necrotic lesions. 16, 18, 27, 31 Thus, all findings of recurrence on MRI and/ or PET were regarded as events and any others as censored. Also, repeat SRS-free survival time was defined as the interval between the first SRS and the day the second SRS was performed for new lesions; all repeat SRS procedures for newly developed lesions were regarded as events and any others as censored. For patients developing new brain metastases after the first SRS, our approach is similar to that in patients with initially diagnosed brain metastases. As to tumor size, if follow-up MRI demonstrates tumors with diameters of 2-3 mm in the brainstem or optic apparatus, we perform repeat SRS without further observation. Otherwise, repeat SRS is usually postponed with close MRI follow-up until the tumor diameter exceeds approximately 1 cm. Neurological deterioration-free survival time was defined as the interval between the first SRS and the day that any brain disease-caused neurological worsening manifested (that is, local recurrence, progression of new lesions, and SRS-induced complications). Decreases in KPS scores, in patients with scores of 20% or less, due to neurological worsening were regarded as events and any others as censored. Major complication-free survival time was taken as the interval between the first SRS and the day major SRS-induced complications occurred. Patients with major complications included those with Radiation Therapy Oncology Group (RTOG) neurotoxicity grades of 2 or worse and, even if the grade was either 0 or 1, those in whom surgical intervention was required based on sequential MRI follow-up demonstrating progressive enlargement of a cyst and/or a mass lesion with further observation thus being regarded as excessively high risk; all of these conditions were regarded as events and any others as censored.
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Statistical Analysis
Data were analyzed according to the intention-to-treat principle. For the baseline variables, summary statistics were constructed using frequencies and proportions for categorical data and medians and ranges for continuous variables. We compared patient characteristics using the Fisher exact test for categorical outcomes and t-tests for continuous variables, as appropriate. The Kaplan-Meier method was used for overall survivals.
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For time-to-event outcomes, the cumulative incidences of local recurrence, repeat SRS, neurological deterioration, and major complications were estimated employing competing risk analysis, because death is a competing risk for loss to follow-up (that is, patients who die can no longer become lost to follow-up). 5, 6, 23 Also, to identify baseline and clinical variables associated with the 4 aforementioned outcomes, competing risk analyses were performed with the Fine-Gray generalization of the proportional hazards model accounting for death as a competing risk. 3 Fine-Gray generalization makes use of the subdistribution hazard to model cumulative incidence, thereby quantifying the overall benefit or harm of an exposure. 2 All comparisons were planned and the tests were 2-sided. A p value of less than 0.05 was considered to be statistically significant. All statistical analyses were performed by one of the authors (Y.S.) using SAS software version 9.3 (SAS Institute) and the R statistical program, version 3.0.0. Before statistical analyses, the database was cleaned by another author (Y.H.). These 2 authors were not involved in either SRS treatment or patient follow-up.
Results
Cohort Studies
The overall median survival time (MST) after SRS for the 2552 patients whose cases were recorded in our database was 7.4 months (95% CI 7.1-7.9 months). In the herein-reported subset (1346 patients ≥ 65 of age, none lost to follow-up), the median post-SRS follow-up time among censored observations (39 cases) was 41.9 months (range 1.2-145.5 months), and 1307 patients (97.1%) had died as of August 2013. The MST after SRS was 7.0 months (95% CI 6.4-7.4 months). Actuarial post-SRS survival rates were 54.8%, 31.1%, 13.0%, 7.4%, and 3.5% at the 6th, 12th, 24th, 36th, and 60th post-SRS month, respectively. Among the 1302 deceased patients, causes of death could not be determined in 30, but were confirmed in the remaining 1277 to be non-brain disease in 1149 (90.0%) and brain disease in 128 (10.0%).
Studies of Case-Matched Subset
As described above, after all of the propensity score matches had been performed, we compared baseline characteristics between the 2 groups. Ultimately, 330 patients (165 in each group) were selected. The p values after matching were over 0.05 for all clinical factors ( Table 2) .
As shown in Fig. 1 , although the post-SRS MST was shorter in Group A (5.3 months) than in Group B (6.9 months) patients, this difference was not statistically significant (HR 1.147, 95% CI 0.921-1.429, p = 0.22). Incidences of neurological death and deterioration were slightly lower in Group A than in Group B patients (6.3% vs 11.8% and 8.5% vs 13.9%, respectively), but these differences did not reach statistical significance (Table 3) . Also, time-to-event outcome studies using competing risk analysis showed that cumulative incidences of neurological death and deterioration were slightly lower in Group A than in Group B. However, there were no significant differences between the 2 groups (HR 0.734, 95% CI 0.346-1.559, p = 0.42 and HR 0.662, 95% CI 0.341-1.285, p = 0.22) ( Table 4) .
Post-SRS follow-up MRI studies were available for 206 patients (63%): 95 in Group A and 111 in Group B. The incidences of local recurrence were similar, 5.2% in Group A and 7.2% in Group B (p = 0.76) patients (Table  3) . Also, there was no significant difference between the 2 groups in the cumulative incidence of local recurrence, estimated using competing risk analysis (HR 0.830, 95% CI 0.268-2.573, p = 0.75) ( Table 4) .
Regarding post-SRS salvage treatment, although rates of repeat SRS and WBRT were slightly lower in Group A than in Group B patients (14.6% vs 21.2% and 1.2% vs 3.0%), these differences did not reach statistical significance (Table 3) . Also, a time-to-event outcome study using competing risk analysis showed that cumulative rates of repeat SRS were slightly lower in Group A than in Group B patients, although the difference was not statistically significant (HR 0.738, 95% CI 0.438-1.242, p = 0.25) ( Table 4) . One patient (0.6%) in each of the 2 groups underwent salvage surgery (p = 1.00) ( Table 3) .
As shown in Table 4 , cumulative incidences of SRSrelated complications estimated using competing risk analysis did not differ significantly between the 2 groups (HR 0.616, 95% CI 0.152-2.495, p = 0.49).
Among the Group A patients, the post-SRS MSTs were 11.6 months (95% CI 7.8-19.6 months), 7.9 months (95% CI 5.2-10.9 months), and 2.8 months (95% CI 2.4-4.6 months) for modified-recursive partitioning analysis (RPA) ( Table 5 ) Classes I+IIa, IIb, and IIc+3, respectively (p < 0.001) (Fig. 2 upper) . 30, 33, 34 The corresponding post-SRS MSTs for Group B patients were 14.3 months (95% CI 8.7-21.3 months), 7.1 months (95% CI 4.8-9.2 months), and 3.9 months (95% CI 2.8-5.2 months) (p < 0.001) (Fig. 2 lower) . In patients with modified-RPA Class I+IIa disease, MSTs were very similar in Groups A and B (7.9 and 7.1 months, HR 0.938, 95% CI 0.624-1.406, p = 0.76). In patients with modified-RPA Classes I+IIa and IIc+III disease, MSTs in Group A were shorter than those in Group B (11.6 vs 14.3 months and 2.8 vs 3.9 months), but these differences did not reach statistical significance (HR 1.327, 95% CI 0.767-2.292, p = 0.31 and HR 1.059, 95% CI 0.784-1.433, p = 0.71). 
Discussion
Is SRS a Reasonable Treatment for Brain Metastases in Patients 80 Years or Older?
In general, most physicians consider patients with brain metastases who are over 65 years of age to be unfavorable candidates for aggressive treatment (surgery, WBRT, or SRS). However, during the 15-year-period of the present study, there have been several reports on treatment of patients with brain metastases in this age group (Table 6 ). Noel et al. 19 reported, based on 117 brain metastasis patients who were 65 years of age or older and underwent Linac-based SRS, that post-SRS MST was 8 months and actuarial survival rates were 58% ± 5% and 13% ± 4% at the 6th and 24th post-SRS months. Minniti et al. 17 reported, based on 102 patients with brain metastases who were 70 years of age or older and underwent SRS, that post-SRS MST was 13.2 and that the 1-and 2-year survival rates after SRS were 63% and 28%. The 1-and 2-year post-SRS local control rates in their study were 90% and 84%. Kim et al. 13 reported, based on 44 patients with brain metastases who were 75 years of age or older and underwent SRS (57%) or SRS plus WBRT (43%), that the MST from the time of diagnosis of brain metastasis was 7.3 ± 1.65 months. These results support applying SRS more aggressively for patients with brain metastases who are 70 years and older, or even those 75 years and older. However, there is little information on SRS for patients with brain metastases who are 80 years of age and older.
In our present case-matched study, the post-SRS MST difference, 1.6 months, between Groups A (5.3 months) and B (6.9 months) was not statistically significant. Furthermore, even among Group A patients, there are subsets in which longer survival can be expected (> 6 months or even ~ 12 months after SRS) (Fig. 2) . It is generally recognized that the main goal in caring for a patient with brain metastasis, regardless of the patient's age, is amelioration of neurological symptoms and/or prevention of status deterioration by avoiding worsening of neurological symptoms and, eventually, neurological death. The present study clearly demonstrated Group A patients to have noninferior results in terms of both neurological deterioration and death as compared with Group B patients. Also, Group A patients were demonstrated to have noninferior results as compared with Group B patients in terms of local recurrence, repeat SRS required for new tumors, salvage WBRT and surgery, or SRS-related complications.
Is Dose De-Escalation Necessary in Elderly Patients?
There is no solid consensus regarding whether dose de-escalation is necessary in SRS treatment for elderly patients. In our recently published study based on 167 patients with brain metastases who survived at least 3 years after SRS, neither patient age nor radiosurgical dose was a significant predictor of long-term complications. 31 Also, in our herein-reported cohort study based on 2552 patients, including some younger than 65 years of age, neither patient age (≥ 65 vs < 65 years, HR 1.166, 95% CI 0.707-1.924, p = 0.55) nor minimum doses (as continuous variables, HR 1.003, 95% CI 0.933-1.086, p = 0.93) impacted cumulative incidences of SRS-related complications. Therefore, dose de-escalation is considered to be unnecessary for elderly patients receiving SRS.
Is WBRT Necessary With SRS?
Controversy persists as to whether SRS+WBRT is superior to SRS alone for treating brain metastases, because when patients are treated with SRS alone, microscopic tumors will still grow, and salvage SRS or WBRT will be required soon after the initial SRS. Thus, WBRT has generally been advocated. However, WBRT can be expected to prevent new tumors arising within 6-8 post-WBRT months at the longest, as shown in Fig. 2 of the report by Aoyama et al. 1 We should remember that con- siderable numbers of patients with brain metastases can survive more than 1 year, outliving the effects of WBRT. Tsao et al. conducted a meta-analysis using data from previously published randomized controlled trials comparing SRS alone vs SRS plus WBRT. 26 They concluded that, although additional WBRT improved distal and local control, SRS alone should be considered a routine treatment option due to favorable neurocognitive outcomes, less risk of late side effects, and the absence of adverse effects on patient performance status.
Fortunately, we already live in an era when a metastatic lesion with a diameter of 2 mm or even slightly smaller can be detected using thin-slice, Gd-enhanced MR images. 8 Hanssens et al. 7 recently reported that SRS alone, based on high-resolution MRI, decreased the incidence of and increased the time until distant recurrences. In fact, although data on periods between SRS and the appearance of new lesions were not available, the present study showed that rates of repeat SRS for new lesions were relatively low, 14.6% and 21.1% in our Groups A and B (Table 3) . Cumulative rates of repeat SRS for new lesions were particularly low in our Group A patients, being 9.1%, 12.7%, 13.9%, and 13.9% at the 6th, 12th, 24th, and 36th post-SRS months, respectively. As we recently reported elsewhere, based on our cohort study including all age groups, the rate of repeat SRS for new lesions was 30.5%. We can reasonably speculate that most physicians would not have recommended further aggressive treatment for considerable numbers of elderly patients with brain metastases, even if new lesions appeared on MR images, because of advanced age.
Weaknesses of the Present Study
The major weakness of a retrospective study might be that clinical factors are obviously heterogeneous. As our previous reports described these issues in detail, they are not repeated herein. 29 Briefly, the characteristics of patients receiving a particular treatment regimen are considered to have a major influence on treatment selection. This is an important issue when estimating the effects of treatments or exposures on outcomes using observational data. One approach to reducing or eliminating the effect of treatment selection bias and confounding effects is to use propensity score matching, which allows one to design and analyze an observational (nonrandomized) study that mimics some of the characteristics of a randomized controlled trial. Therefore, in the present investigation, a case-matched study was also conducted by one of the authors (Y.S.), who did not participate in other aspects of this study and was blinded to final outcomes. Nevertheless, because this was a retrospective study, even if case matching were to be applied, biases in patient selection, original cancer treatments over time, follow-up (outcome, toxicity, and imaging), observers, and so on, could not be eliminated. 33 The values in parentheses after subclasses refer to scores on the subclassification system for RPA Class II, which are based on the sum of a patient's scores for each of the following: KPS score, 90-100 (0) vs 70-80 (1); tumor number, solitary (0) vs multiple (1); controlled primary tumor, yes (0) vs no (1); extracerebral metastases, no (0) vs yes (1).
As clarified in the Patient Population section of Methods, another potential weakness might be that meticulous follow-up was lacking in approximately 25% of our cohort. However, most of these patients died rather early due to systemic disease progression before SRS-induced complications could have occurred. Furthermore, with respect to these complications, only patients with RTOG neurotoxicity Grade 2 or worse were counted in this study, because, if severe problems, not only those that were symptomatic but also those detectable only on MRI, occurred in SRS-treated patients, every physician, without exception, consulted us; however, some busy physicians actually forgot to report minor problems like RTOG neurotoxicity Grade 0 or 1 to us. Therefore, a potential weakness of this study is that some minor complications may not have been included.
How Should Candidates for SRS be Selected From Among Elderly Patients With Brain Metastases?
How to select good candidates for SRS alone, even from among patients 80 years of age or older, is a very important issue. As numerous factors (including the primary cancer site, systemic disease condition, neurological symptoms, numbers and sizes of brain metastases) impact outcomes, clinicians are often uncertain as to the optimal treatment-WBRT, surgery, SRS or radiotherapy, anticancer agent administration, or combinations of these modalities, efficacies of which vary among patient subsets. An improved prognostic index might resolve some of the uncertainty in making treatment decisions as well as guiding future research efforts. Although 5 prognostic grading indices for initially treated brain metastasis patients, RPA, Score Index for Radiosurgery (SIR), 28 Basic Score for Brain Metastases (BSBM), 14 Graded Prognostic Assessment (GPA) 24 and modified RPA 30, 33, 34 are well established, the RPA, SIR, and GPA incorporate age factors and therefore are not applicable to elderly patient subsets. The BSBM incorporates no brain metastasis-related factors-neither tumor number nor tumor size, both of which are widely accepted as major factors influencing patient survival periods. Sperduto et al. recently modified their GPA system to derive the Diagnosis-Specific GPA (DS-GPA). 25 Their new system uses a different scoring method, which takes into account different primary tumor types. Six common types of primary cancer associated with brain metastases (non-small cell lung cancer, small cell lung cancer, breast cancer, melanoma, renal cell cancer, and gastrointestinal cancer) were scored to allow comparison of post-WBRT survival rates. However, among the 6 original tumor categories, DS-GPA can be used for elderly brain metastasis patients only with breast cancer or gastrointestinal cancer because age factors are incorporated. Although the database that was used in the present paper included approximately 80% of the patients whose data were used for deriving the modified-RPA system in our previous publication, 33 we intended to prove, in the present study, that this system is potentially useful for selecting favorable candidates among a small subset of elderly patients who are 65 years of age or older, or even 80 years of age or older. A possible criticism of this system is that the subgroup designation of Class I+IIa may not be appropriate because there were no original RPA Class I patients. Since yet another new index for elderly patients with brain metastases might result in even greater uncertainty among clinicians, we used the modified-RPA system for the present study.
Conclusions
Our results suggest that carefully selected patients 80 years of age or older are not poor candidates for SRS as compared with those 65-79 years old. Particularly, among patients 80 years of age or older, those in modified-RPA Class I+IIa or IIb are considered to be favorable candidates for more aggressive treatment of brain metastases.
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